Peregrine's partnership prospects, stock soar after bavituximab doubles overall survival in NSCLC
22:35 EDT 9 Sep 2012 | SCRIP
Peregrine Pharmaceuticals' stock price soared 46.6% on 7 September after the company announced that bavituximab plus the chemotherapy standard docetaxel doubled median overall survival (OS) compared to docetaxel alone, according to the interim.....
Original Article: Peregrine's partnership prospects, stock soar after bavituximab doubles overall survival in NSCLC
More From BioPortfolio on "Peregrine's partnership prospects, stock soar after bavituximab doubles overall survival in NSCLC"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
